Results 181 to 190 of about 55,246 (249)

The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort. [PDF]

Ther Adv Musculoskelet Dis
Moschetti L, Rovaris S, Bonomi F, Codes-Mendez H, Martín-López M, Cacciapaglia F, Tonutti A, Galdo FD, Campochiaro C, Truchetet ME, Allanore Y, Kuwana M, Bruni C, Santos CS, Moroncini G, Caetano J, Granel B, Groseanu L, Pedretti E, Colombo E, Guerini M, Pereira Silva M, Bearzi P, Belloli L, Alegre-Sancho JJ, Maglio C, Cuomo G, Parvu M, Poormoghim H, Idolazzi L, Andréasson K, De Santis M, Iannone F, Carreira PE, Castellví I, Guiducci S, Cavazzana I, Franceschini F, Airò P, Lazzaroni MG.   +39 more
europepmc   +1 more source

Immune checkpoint inhibitor-associated scleroderma refractory to corticosteroids: Clinical improvement with intravenous immune globulin and dupilumab. [PDF]

JAAD Case Rep
Abul-Enin DG, Edmonds NL, Rusu CA.
europepmc   +1 more source

Systemic scleroderma.

Minnesota medicine, 1966
openaire   +1 more source

Increased Xanthine Oxidoreductase Activity in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. [PDF]

CHEST Pulm
Coursen JC, Tuhy T, Woods A, Hummers LK, Shah AA, Hassoun PM, Damico RL, Mathai SC, Simpson CE.   +8 more
europepmc   +1 more source

Cervical Spine Involvement in Morphea Patients With Subclinical Neurologic Signs. [PDF]

Cureus
Critelli M, Davis T, Flume H, Sarameh Y, Baer CB, Shabbir R, Schwartz JT.   +6 more
europepmc   +1 more source

[On systemic scleroderma].

Terapevticheskii arkhiv, 1998
Ts, ISTAMONIVA, S I, RIABOV
openaire   +1 more source